Roivant Sciences
https://roivant.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Roivant Sciences
ADCs, Oncology Move To Fore In Korean Biopharma Alliances
Although there weren’t many large-scale partnerships as in previous years, Korean biopharma firms were involved in a broad range of deals across diverse therapeutic areas in 2020, with ADCs, oncology and domestic alliances emerging as key trends.
Roivant Alliance Takes SK Into Cancer, Intractable Diseases
Korea's SK Group expands its biopharma business via a sizable investment in Roivant's protein degradation platform, through which the partners aim to progress candidates in cancer, immunology and neurology, with the first entering the clinic next year.
Urovant’s Vibegron Flops In IBS Study
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Deal Watch: Lilly Finds New Partners For Genetic Disorders, Protein Degradation
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Altavant Sciences
- Alyvant
- Aruvant Sciences
- Axovant Sciences
- Cyotvant Sciences
- Datavant
- Dermavant Sciences
- Enzyvant
- Genevant
- Immunovant Sciences
- Metavant Sciences
- PhaseRx
- Respivant
- Roivant Health
- Roivant Neurosciences Ltd
- Roivant Pharma
- Roivant Sciences Ltd.
- Inc.
- Sinovant Sciences
- Sumitovant Biopharma Ltd.
- Valor Biotechnology
- Axovant Gene Therapies Ltd.